

Supplemental Table S7. Association of Clinical Characteristics with Duration of GH treatment Interruption (Years) at Re-Evaluation in Patients with Organic Growth Hormone Deficiency

Outcome variable	Unadjusted, β (95% CI)	Adjusted, β (95% CI) ^c
Body mass index, kg/m ²	0.12 (-0.11 to 0.35)	-0.03 (-0.34 to 0.27)
Body mass index Z-score	0.04 (-0.04 to 0.12)	-0.01 (-0.11 to 0.10)
IGF-1, μ g/L	-4.45 (-7.67 to -1.24) ^b	-2.15 (-5.98 to 1.67)
IGFBP-3, μ g/L	-69.75 (-112.67 to -26.82) ^b	-50.98 (-104.47 to 2.50)
Fasting glucose, mg/dL	0.49 (-0.11 to 1.09)	0.87 (0.09 to 1.65) ^a
Glycated hemoglobin, %	0.01 (-0.02 to 0.04)	0.00 (-0.04 to 0.04)
Total cholesterol, mg/dL	2.02 (0.41 to 3.63) ^a	1.61 (-0.54 to 3.76)
Triglyceride, mg/dL	4.54 (-1.44 to 10.52)	3.72 (-4.38 to 11.81)
HDL cholesterol, mg/dL	-1.20 (-2.18 to -0.23) ^a	-0.95 (-2.25 to 0.35)
LDL cholesterol, mg/dL	3.57 (1.19 to 5.95) ^b	2.23 (-0.93 to 5.38)
Non-HDL cholesterol, mg/dL	4.86 (2.48 to 7.25) ^b	3.39 (0.20 to 6.58) ^a

GH, growth hormone; CI, confidence interval; IGF-1, insulin-like growth factor-1; IGFBP-3, IGF-binding protein-3; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

^a $P < 0.05$; ^b $P < 0.01$; ^cModels were adjusted for age, sex, peak growth hormone levels at re-evaluation for body mass index and body mass index Z-scores; the models were adjusted for age, sex, body mass index Z-scores, and peak GH levels for other parameters.